1. Hahn BH, Karpouzas GA, Tsao BP. Systemic lupus erythematosus and related syndromes. Pathogenesis of systemic lupus erythematosus. In:Kelley’s Textbook of Rheumatology (Volume 2).Harris ED, Budd RC, Firestein GSet al.(Eds). Elsevier Saunsers, PA, USA 1174–1200 (2005).
2. Furie R, Lisse J, Merrill JTet al.Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator BLyS.) improves or stabilizes SLE activity in a multicenter Phase 2 trial.Program and abstracts of the American College of Rheumatology 70th Annual Meeting.Washington, DC, USA, November 11–15, 2006.
3. Strand V, Crawford B, Petri Met al.Patients with active systemic lupus erythematosus (SLE) treated with belimumab improve health-related quality of life (HRQOL) in a randomized controlled trial (RCT).Program and abstracts of the American College of Rheumatology 70th Annual MeetingWashington, DC, USA, November 11–15, 2006.
4. Wallace DJ, Lisse J, Stohl Wet al.Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks.Program and abstracts of the American College of Rheumatology 70th Annual Meeting.Washington, DC, USA, November 11–15, 2006.
5. Dall’Era M, Chakravarty E, Genovese Met al.Trial of atacicept in patients with system lupus erythematosus (SLE).Program and abstracts of the American College of Rheumatology 70th Annual Meeting.Washington, DC, USA, November 11–15, 2006.